Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05081492 | CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 |
| clinicaltrials |
| NCT05780567 | Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | active not recruiting | Phase 3 | 1,946 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03377387 | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03435952 | Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | active not recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04125914 | Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families | active not recruiting | N/A | 384 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02754752 | Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment | active not recruiting | Phase 2 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03162627 | Selumetinib and Olaparib in Solid Tumors | active not recruiting | Phase 1 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03546972 | Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants | active not recruiting | N/A | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06840483 | Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | active not recruiting | Phase 2 | 66 | BicycleTx LimitedINDUSTRY | 7 | Apr 15, 2026 | clinicaltrials |
| NCT04920708 | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression(FAIM) | active not recruiting | Phase 2 | 57 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03650894 | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | active not recruiting | Phase 2 | 30 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04650581 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor(FINER) | active not recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT04895761 | Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer | active not recruiting | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05215769 | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer | active not recruiting | N/A | 243 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06702618 | Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer | active not recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04496739 | Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE) | active not recruiting | N/A | 412 | SWOG Cancer Research NetworkNETWORK | 2 | Apr 7, 2026 | clinicaltrials |
| NCT07515300 | Impact of the ARM Technique on the Prevention of Lymphedema After Axillary Lymphadenectomy: A Multicenter Randomized Clinical Trial(ARM-LIFE) | active not recruiting | N/A | 100 | Hospital Universitari de BellvitgeOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03822312 | A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy | active not recruiting | N/A | 30 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02295059 | Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention | active not recruiting | N/A | 80 | City of Hope Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04916808 | The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing(AUS-PREDICT) | active not recruiting | — | 1,500 | PreludeDxINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04851613 | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | active not recruiting | Phase 3 | 256 | Laekna LimitedINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05568472 | Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study | active not recruiting | N/A | 565 | SWOG Cancer Research NetworkNETWORK | 2 | Apr 2, 2026 | clinicaltrials |
| NCT07023198 | Clinical Breast Examination and Patient Navigation Intervention in Sub-Saharan Africa | active not recruiting | N/A | 8,000 | Addis Ababa UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02890082 | Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer(PRESAGE) | active not recruiting | Phase 2 | 102 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06932133 | A Trial on the Use of Point-of-care Ultrasound in the Assessment of Breast Symptoms(Breast-POCET) | active not recruiting | N/A | 600 | Region SkaneOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04216576 | A Study of the Use of Text Message Reminders to Take Palbociclib | active not recruiting | N/A | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06060938 | Personalized Breast Cancer Screening(PRSONAL) | active not recruiting | N/A | 2,200 | Herlev and Gentofte HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07498400 | Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer | active not recruiting | N/A | 216 | Xijing HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01030250 | Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life | active not recruiting | — | 238 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05318274 | Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. | active not recruiting | N/A | 72 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Mar 23, 2026 | clinicaltrials |
| NCT00185744 | Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer | active not recruiting | N/A | 121 | Stanford UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04068623 | Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients(PERCEPTION) | active not recruiting | — | 90 | Centre Jean PerrinOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07484776 | Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer | active not recruiting | N/A | 40 | Universidad Europea de MadridOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT02089100 | Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer(STEREO-SEIN) | active not recruiting | Phase 3 | 154 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT01570998 | Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery | active not recruiting | N/A | 1,259 | University of California, San FranciscoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02871167 | Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation(CHACRY) | active not recruiting | N/A | 140 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03795246 | Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer(KSF2) | active not recruiting | N/A | 132 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT02482376 | Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer | active not recruiting | Phase 2 | 110 | Duke UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05662345 | ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)(ACT-MBC) | active not recruiting | — | 65 | Menarini Silicon Biosystems, INCINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03742245 | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | active not recruiting | Phase 1 | 28 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials